
Last updated: 2026-09-06 06:28:20. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
XORTX Therapeutics Inc. (XRTX) operates in the -- sector and is listed on NASDAQ. The stock is currently priced at $2,31, with a market capitalization of $4,51M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $1,73 to $7,05. This page covers its latest market performance, valuation, price trends and company information.
$4,51M | |
$2,29 | |
$1.513,35 | |
$1,73 | |
$2,15 | |
12,52K | |
-- | |
-- | |
$7,05 | |
$1,73 | |
-- | |
-- |
XORTX Therapeutics Inc. (XRTX) last closed at $2,15 as of 2026-09-04 20:01:00, unchanged from the previous close of $2,15.
During the latest regular trading session, XRTX traded between $1,73 and $1.513,35, with a volume of 12,52K shares. The closing price was near the lower end and near the lower end of its 52-week range.
Over the past seven days, XORTX Therapeutics Inc. (XRTX) moved from $2,18 to $2,31, representing a gain of 5,96% ($0,13).
The stock traded between $2,20 and $2,45 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 14,22 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 11,0%
XRTX is currently trading at $2,31, placing it 11,0% of the way from its 52-week low of $1,73 to its 52-week high of $7,05. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.
| Employees | 3 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of XORTX Therapeutics Inc. (XRTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.